EcoDrugPlus

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSLBEG00000002801
Gene Symbol: WEE1
3 Cross references
205 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSLBEG00000016096
Gene Symbol: YES1
4 Cross references
207 Possible Orthologues:

Acetylcholinesterase

Ensembl ID : ENSLBEG00000028009
Gene Symbol: ACHE
1 Cross references
187 Possible Orthologues:

Acetylcholinesterase-Like

Ensembl ID : ENSLBEG00000002254
Gene Symbol: LOC110000928
3 Cross references
230 Possible Orthologues:

Acetylcholinesterase-Like

Ensembl ID : ENSLBEG00000020901
Gene Symbol: LOC109976574
3 Cross references
230 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSLBEG00000015020
Gene Symbol: ACVR2B
3 Cross references
195 Possible Orthologues:

Activin A Receptor Type 2ba

Ensembl ID : ENSLBEG00000020683
Gene Symbol: ACVR2BA
1 Cross references
193 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSLBEG00000011329
Gene Symbol: ADORA1
4 Cross references
203 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSLBEG00000003146
Gene Symbol: ADORA2A
3 Cross references
198 Possible Orthologues:

Adenosine A2a Receptor A

Ensembl ID : ENSLBEG00000000613
Gene Symbol: ADORA2AA
1 Cross references
189 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSLBEG00000015925
Gene Symbol: ADORA2B
3 Cross references
199 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSLBEG00000002977
Gene Symbol: ADORA3
3 Cross references
142 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).